Medical stocks are heating up

If you are an active trader you have probably noticed the recent rush on medical stocks. I don't think this broad concept of one size fits all works here but some specific sectors within the medical field seem to be enjoying some exposure and the investors have fallen in love. The beauty is these are not effected by the price of gold or the turmoil in Europe. The world needs drugs and they have to diagnose these diseases as well.

Three companies have come onto my watch list and I feel they have been overlooked until now that is. These all have a rather attractive share structure IMHO and an active participation by institutions and insiders. They all have recent news and have been ticking off milestones as promised. What more could you ask for in today's economy?

These are stocks I am keeping a close eye on in the days and weeks to come. Remember some similar medical stocks have enjoyed huge runs on their share price in days.

Verisante Technology Inc  VRS.V

http://www.verisante.com/news/media/ 

The Verisante Aura™ for skin cancer detection and the Verisante Core™ series for lung, colon and cervical cancer detection utilize a proprietary cancer detection platform while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and the University of British Columbia and tested and refined on approximately 1,000 lesions at the Skin Care Centre at Vancouver General Hospital.

This exclusive platform technology allows Verisante to develop and offer a range of compact, non-invasive cancer detection devices that offer immediate results for many of the most common cancers.

Verisante is ISO 13485:2003 certified as a medical device manufacturer.

Verisante Technology, Inc. focuses in the commercialization of systems for the early detection of cancer. The Company’s initial focus is skin cancer, including basal cell carcinoma, squamous cell carcinoma, and melanoma. The Company has licensed a technology developed by the BC Cancer Agency for in vivo, real-time, non-invasive skin measurements. This platform technology may also be applied to early detection systems for other types of cancer, including lung, GI, colorectal, and cervical cancers. Verisante’s skin cancer detection device is a multimodality imaging and spectroscopy system designed to aid in the early detection of skin cancer. This system uses a technology to scan lesions and provides instant, real-time results. This system will help to automate the process of skin cancer diagnosis. 

 

MIRACULINS INC MOM.V

http://www.miraculins.com/the_miraculins_advantage.aspx 

Miraculins focuses on in-licensing/acquiring and developing both cancer and non-cancer diagnostic opportunities that have completed early stage research and address unmet clinical needs.
Miraculins’ internal research program has lead to the discovery and identification of prostate cancer biomarkers, the lead marker of which is called Prostate Secretory Protein or PSP94. Miraculins also acquired several biomarkers in the areas of Gastric, Colorectal, and Pancreatic Cancer and are in the process of moving those programs further through the pipeline.
With the experience gained from developing its first assay, and the addition of a strong scientific team, Miraculins has developed a process and criteria for evaluating technologies as potential licensing targets.
Once Miraculins has determined that a specific technology meets its criteria the Company adds value to the early stage research by developing a clinical grade assay, confirming the diagnostic potential of the technology and moving the test through to regulatory approval and commercial sales. 
Miraculins therefore bridges the gap between early stage research, completed at the university/institution level, and clinical grade commercial assays.
Under its new business model, Miraculins has acquired a panel of Preeclampsia biomarkers from Mount Sinai Hospital and partnered the program with Inverness Medical Innovations (NYSE:IMA), one of the world’s largest diagnostic companies.

Abattis Biologix FLU on the CNSX
http://www.abattis.com/s/home.asp

Abattis Biologix is a specialty biotechnology company engaged in the licensing, marketing and formulation of unique and proprietary botanical, vitamin, and mineral products in several high growth natural health categories. The Company owns patent pending rights tested and proven formulas to a method of preventing and treating avian influenza in humans The company also owns Patent pending IP to a METHOD OF COMPOSITION FOR PREVENTING AND TREATING AVIAN INFLUENZA IN POULTRY. This IP is being licensed to countries around the world which will enable the company to focus on formulation and innovative delivery systems in the areas of Women's and Children's Health and MicroNutrient Fortification, Cognitive Health, Histamine and Anti-Inflammatory Solutions. 

Abattis Biologix Corporation (the "Company") was founded in 2009 and assembled a team of people who shared a vision of making a difference and helping. We all feel that there is a growing global need for a nature-based solution to viral infection. We seek to give back and offer aid through the commercialization of two latter stage highly effective natural botanical antiviral products. These antiviral formulations have been tested and the tests show that the products seem to have significant effect against the effects of viral infections such as influenza (the "Flu") and it's many mutated forms; Swine, Bird and SARS are a few common examples. 

CONTENT POSTED ON THIS BLOG DOES NOT CONSTITUTE A BUY OR SELL RECOMMENDATION. MANY OF THE COMPANIES PROFILED HERE I AM NOT INVESTED IN AND DO NOT INTEND TO INVEST IN. THESE ARE MERELY MY THOUGHTS ON MARKET CONDITIONS AND STOCK VALUATIONS. INVESTING IN THE STOCK MARKET CAN BE VERY RISKY AND YOU SHOULD ALWAYS CONSULT AN INVESTMENT PROFESSIONAL BEFORE MAKING ANY DECISIONS. ULTIMATELY YOU ARE RESPONSIBLE FOR CONDUCTING YOUR OWN DUE DILIGENCE AND PROTECTING YOUR MONEY.